University President Richard Levin underwent surgery for prostate cancer on Thursday and will temporarily cede his administrative duties to colleagues as he recovers. Though Vice President and Secretary Linda Lorimer said the procedure was successful and Levin’s prognosis is “excellent,” the president will stay out of his Woodbridge Hall office for approximately three weeks. During that time, …

An experimental “vaccine” that offers a new approach to fighting prostate cancer added four months to the lives of men with advanced stages of the disease, doctors report.

CHICAGO – An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday.

UroToday.com – In the March 18 issue of the Journal of the National Cancer Institute, Dr. Jane Figueiredo and colleagues reported on the relationship between folic acid and prostate cancer (CaP). Folate is important in methylation reactions and nucleotide synthesis.

UroToday.com – This study reported in Cancer, Epidemiology, Biomarkers and Prevention used the same Prostate, Lung, Colorectal and Ovarian (PLCO) database as that by Andriole and colleagues in the NEJM article recently covered in Urotoday1. It is previously proposed that PSA levels in obese men could be due to hemodilution secondary to increased circulating blood volume.

The recent announcement of the REDUCE trial results at the American Urological Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has shown to lower by 23 percent the risk of prostate cancer in men with an increased risk of the disease.

On 22 and 23 June 2009, the Prostate Cancer Translational Research in Europe (PCTRE) meeting will be held in the Beurs van Berlage in Amsterdam (NL). Translational research transforms scientific discoveries arising from laboratory, clinical or population studies into clinical applications to reduce cancer incidence, morbidity and mortality. The European Association of Urology (EAU) provides an excellent forum to disseminate knowledge in specialised meetings.

Sylvester Comprehensive Cancer Center, part of UHealth-University of Miami Health System, announced it is the first cancer-care program in the region enabling clinicians to accurately manage delivery of radiation to prostate cancer tumors through a new technology called the Calypso® 4D Localization System™. The System enables precision-guided radiation therapy delivery to the prostate with continuous, objective, organ-motion detection and monitoring.

Beyond lowering cholesterol, statin medications have been found to have numerous other health benefits, including lowering a healthy man’s risk of developing advanced prostate cancer, as well as lowering his prostate-specific antigen (PSA) levels.

With the news of Dendreon Corporation’s announcement yesterday at the annual meeting in Chicago of the American Urological Association that its investigational active cellular immunotherapy for advanced prostate cancer, PROVENGE (sipuleucel-T), extended patient survival by 4.